KBC Group NV acquired a new stake in CryoLife, Inc. (NYSE:CRY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,250 shares of the medical equipment provider’s stock, valued at approximately $165,000.
Several other hedge funds and other institutional investors have also bought and sold shares of CRY. Municipal Employees Retirement System of Michigan lifted its stake in CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after acquiring an additional 190 shares during the last quarter. Mason Street Advisors LLC raised its holdings in CryoLife by 7.4% during the first quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 438 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in CryoLife by 80.8% during the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock worth $107,000 after purchasing an additional 2,407 shares in the last quarter. First Mercantile Trust Co. raised its holdings in CryoLife by 5.6% during the second quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after purchasing an additional 291 shares in the last quarter. Finally, Creative Planning raised its holdings in CryoLife by 3.0% during the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after purchasing an additional 200 shares in the last quarter. 68.85% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently commented on CRY shares. Zacks Investment Research raised shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Thursday, June 8th. BidaskClub cut shares of CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. CryoLife currently has an average rating of “Hold” and a consensus price target of $22.00.
WARNING: This article was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/09/12/kbc-group-nv-acquires-shares-of-8250-cryolife-inc-cry.html.
CryoLife, Inc. (CRY) opened at 22.40 on Tuesday. The firm has a 50-day moving average of $19.46 and a 200-day moving average of $18.19. The stock has a market capitalization of $749.19 million, a price-to-earnings ratio of 67.88 and a beta of 0.97. CryoLife, Inc. has a 12-month low of $14.02 and a 12-month high of $22.85.
CryoLife (NYSE:CRY) last announced its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The firm had revenue of $47.80 million during the quarter, compared to analyst estimates of $47.02 million. During the same period last year, the company posted $0.13 EPS. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities research analysts forecast that CryoLife, Inc. will post $0.43 earnings per share for the current fiscal year.
In other CryoLife news, CEO James P. Mackin sold 125,000 shares of CryoLife stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the transaction, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,768,761.99. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James P. Mackin sold 43,050 shares of CryoLife stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total value of $950,974.50. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares in the company, valued at $8,800,633.91. The disclosure for this sale can be found here. Insiders sold a total of 178,627 shares of company stock worth $3,915,765 over the last three months. 6.00% of the stock is owned by company insiders.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.